Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 14 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 8114851

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Feb 14, 2012 · Expires Feb 9, 2032

    granted

  2. US 8114981

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Feb 14, 2012 · Expires Feb 9, 2032

    granted

  3. US 8114984

    RNAi modulation of Aha and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 14, 2012 · Expires Feb 9, 2032

    granted

  4. US 8110674

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Feb 7, 2012 · Expires Feb 2, 2032

    granted

  5. US 8106022

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Jan 31, 2012 · Expires Jan 26, 2032

    granted

  6. US 8101584

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 24, 2012 · Expires Jan 19, 2032

    granted

  7. US 8101742

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 24, 2012 · Expires Jan 19, 2032

    granted

  8. US 8080532

    Compositions and methods for inhibiting expression of Huntingtin gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 20, 2011 · Expires Dec 15, 2031

    granted

  9. US 8058257

    Compositions and methods for inhibiting expression of a gene from the JC virus

    Alnylam Pharmaceuticals, Inc. · Granted Nov 15, 2011 · Expires Nov 10, 2031

    granted

  10. US 8034793

    RNAi modulation of MLL-AF4 and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Oct 11, 2011 · Expires Oct 6, 2031

    granted

  11. US 8034376

    Lipid containing formulations

    Alnylam Pharmaceuticals, Inc. · Granted Oct 11, 2011 · Expires Oct 6, 2031

    granted

  12. US 8017763

    Chemically modified oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Sep 13, 2011 · Expires Sep 8, 2031

    granted

  13. US 8017762

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Sep 13, 2011 · Expires Sep 8, 2031

    granted

  14. US 8013136

    Oligonucleotides comprising a non-phosphate backbone linkage

    Alnylam Pharmaceuticals, Inc. · Granted Sep 6, 2011 · Expires Sep 1, 2031

    granted

  15. US 8003619

    Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide

    Alnylam Pharmaceuticals, Inc. · Granted Aug 23, 2011 · Expires Aug 18, 2031

    granted

  16. US 7994309

    Compositions and methods for inhibiting expression of a mutant gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  17. US 7994307

    RNAi modulation of the BCR-ABL fusion gene and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  18. US 7985581

    Multiple RNA polymerase III promoter expression constructs

    Alnylam Pharmaceuticals, Inc. · Granted Jul 26, 2011 · Expires Jul 21, 2031

    granted

  19. US 7981869

    RNAi modulation of RSV and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 19, 2011 · Expires Jul 14, 2031

    granted

  20. US 7956177

    dsRNA compositions and methods for treating HPV infection

    Alnylam Pharmaceuticals, Inc. · Granted Jun 7, 2011 · Expires Jun 2, 2031

    granted

  21. US 7947659

    iRNA agents targeting VEGF

    Alnylam Pharmaceuticals, Inc. · Granted May 24, 2011 · Expires May 19, 2031

    granted

  22. US 7928217

    Nuclease resistant double-stranded ribonucleic acid

    Alnylam Pharmaceuticals, Inc. · Granted Apr 19, 2011 · Expires Apr 14, 2031

    granted

  23. US 7919473

    IRNA agents targeting VEGF

    Alnylam Pharmaceuticals, Inc. · Granted Apr 5, 2011 · Expires Mar 31, 2031

    granted

  24. US 7906484

    Complex for transferring an anionic substance into a cell

    Alnylam Pharmaceuticals, Inc. · Granted Mar 15, 2011 · Expires Mar 10, 2031

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.